SCHEMBL24088772

SCHEMBL24088772

CC(C)(C)OC(=O)NCCc1c[nH]c(-c2cc(Cl)cc(Cl)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.42
STK17A Q9UEE5 1/20 0.42
ALDH1A1 P00352 4/20 0.41
HTT P42858 3/20 0.41
HPGD P15428 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
TP53 P04637 1/20 0.41
GLA P06280 1/20 0.41
MAPT P10636 1/20 0.41
XBP1 P17861 1/20 0.41
HSD17B10 Q99714 1/20 0.41
IDO1 P14902 4/20 0.41
LMNA P02545 2/20 0.40
NQO2 P16083 1/20 0.40
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GFER P55789 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24088765 0.88 LMNA (0.47) STK17BSTK17AALDH1A1HTTHPGD
SCHEMBL24088778 0.82 ALDH1A1 (0.48) STK17BSTK17AALDH1A1HTTHPGD
SCHEMBL31668899 0.82 ALDH1A1 (0.48) STK17BSTK17AALDH1A1HTTHPGD
SCHEMBL23778729 0.81 CXCR2 (0.39) ALDH1A1HPGDNPSR1TP53MAPT
SCHEMBL23778705 0.79 GSK3B (0.41) ALDH1A1HPGDMAPTHSD17B10KDM4E
SCHEMBL5691656 0.75 NPSR1 (0.45) STK17BSTK17AALDH1A1HTTNPSR1
SCHEMBL23778648 0.74 MAPT (0.42) HTTMAPTLMNAMEN1KMT2A
SCHEMBL8992436 0.72 NPSR1 (0.43) STK17BSTK17AALDH1A1HTTNPSR1
SCHEMBL2083950 0.71 ALDH1A1 (0.50) STK17BSTK17AALDH1A1HTTNPSR1
SCHEMBL28103097 0.71 HTT (0.48) ALDH1A1HTTHPGDNPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001850-A1 NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) 2026-01-01 US disclosed
US-12378203-B2 Imidazole compounds, process for the synthesis and uses thereof AHAMMUNE BIOSCIENCES PRIVATE LIMITED (IN) 2025-08-05 US disclosed
US-20210380538-A1 NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380538-A1 NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF IDO1, IDO2, NFATC1 STK17B 1031/4885STK17A 662/4885ALDH1A1 670/4885
US-20260001850-A1 NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF MALT1, ADRM1, CYP11B1 STK17B 2728/4885STK17A 1973/4885ALDH1A1 2523/4885
US-12378203-B2 Imidazole compounds, process for the synthesis and uses thereof IDO1, IDO2, NFATC1 STK17B 998/4885STK17A 589/4885ALDH1A1 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.